So, here's a fun Friday for biotech investors: Replimune Group, Inc. (REPL) shares are taking a nosedive, down about 19% as everyone stares at the clock waiting for the FDA to decide the fate of its lead cancer drug. It's one of those days where the stock chart looks like a cliff, and the reason is pretty straightforward—today is decision day for RP1, the company's therapy for advanced melanoma.

This isn't the first rodeo. The FDA is set to rule on a resubmitted Biologics License Application for RP1 in combination with nivolumab. The agency already sent back the application once, with a Complete Response Letter in June 2025 saying the IGNYTE trial didn't quite cut it in proving the drug works. That rejection has, understandably, made investors a bit twitchy about whether round two will go any better.

Why Today's Decision Is a Big Deal

If you're wondering why the stock is getting hammered before the news even drops, well, that's the market pricing in risk. A positive decision could send the shares soaring, but a second rejection? That would be rough. The FDA's review is the kind of binary event that can redefine a biotech company's future overnight.

The FDA's Internal Drama Played a Role

Here's where it gets interesting—and a bit messy. According to a media report from August 2025, the FDA's top cancer drug regulator got involved at the last minute during the initial review of Replimune's treatment. That move reportedly helped sink the approval, even though some folks inside the agency were on board with it. Talk about office politics with high stakes.

Ongoing leadership changes, staff turnover, and general internal issues at the FDA apparently influenced the whole process. Replimune basically got caught in the crossfire of the agency's own turmoil. It's a reminder that drug approvals aren't just about data; sometimes, it's about who's in the room and what mood they're in.

Cash Runway and What Analysts Think

On the financial side, Replimune isn't running on fumes. The company said it has $269.1 million in cash, cash equivalents, and short-term investments, which should keep the lights on into the first quarter of 2027. That's a decent cushion, but obviously, an approval would make that cash go a lot further.

Analysts, for their part, are still leaning bullish. The stock carries a Buy rating with an average price target of $16.60. Recent moves include Piper Sandler raising its target to $14.00 with an Overweight rating on February 5, and Wedbush bumping its target to $19.00 with an Outperform rating on February 4. So, the pros see upside—if the FDA plays along.

As of publication, Replimune shares were down 19.46% at $4.76. Now, we wait.